Company intelligence / Profile preview

ProDa BioTech

Marietta, Georgia, United States

Ownership: Private
Development stage: Other

Overview

ProDa BioTech’s lead candidate, ProAgio, is a recombinant protein that targets integrin αvβ₃ on cancer-associated fibroblasts and angiogenic endothelial cells. It has shown preclinical efficacy in animal models of pancreatic and triple-negative breast cancers by disrupting the tumor stroma barrier, improving drug delivery, and reducing side effects. Clinical development is ongoing with Phase II trials in TNBC and early-stage trials/plans for other solid tumors including pancreatic, liver, lung, prostate, and colorectal cancers. The company has received NIH/NCI funding to advance its programs into clinical studies[1][5][6][7].

Therapeutic areas: Oncology
Modalities: Recombinant protein therapeutics
Industry: Biotech

Drug pipeline

1 asset

proagio

Partnerships

No major pharma partnerships publicly disclosed as of May 2025. The company seeks outlicensing partners/investors at industry conferences.

Beyond the preview

Go deeper on ProDa BioTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProDa BioTech.